Fautrel, Bruno
Alten, Rieke
Kirkham, Bruce
de la Torre, Inmaculada
Durand, Frederick
Barry, Jane
Holzkaemper, Thorsten
Fakhouri, Walid
Taylor, Peter C.
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 3 November 2017
Accepted: 3 March 2018
First Online: 21 March 2018
Compliance with ethical standards
:
: For this type of study formal consent is not required. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.
: Bruno Fautrel has received research grants from AbbVie, MSD and Pfizer, and consultancy fees from AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Janssen, Lilly, Medac, Nordic, Pfizer, Roche, and UCB. Rieke Alten has received research grants from UCB, Lilly, Janssen and Pfizer, and consultancy fees from Roche, UCB, Celgene, BMS, Lilly, MSD, AstraZeneca, Pfizer, Janssen, AbbVie, Biogen, Galapagos and Sandoz. Bruce Kirkham has received research grants from UCB, Lilly, AbbVie and Novartis, and consultancy fees from Lilly, Novartis and Janssen. Peter C. Taylor has received research grants from UCB, Lilly, Janssen and Celgene, and consultancy fees from Roche, UCB, GSK, BMS, Lilly, MSD, Pfizer, Janssen, AbbVie, Biogen, Galapagos and Sandoz. Inmaculada de la Torre, Frederick Durand, Jane Barry, Thorsten Holzkaemper and Walid Fakhouri are all medical members of the International Rheumatology Area at Eli Lilly and Company, and employees of Eli Lilly and Company.